Minerva Neurosciences Company Profile (NASDAQ:NERV)

About Minerva Neurosciences

Minerva Neurosciences logoMinerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company's product portfolio include MIN-101 for the treatment of schizophrenia; MIN-117 for the treatment of major depressive disorder (MDD); MIN-202 (also known as JNJ-42847922) for the treatment of insomnia disorder and adjunctive MDD, and MIN-301 for the treatment of Parkinson's disease. MIN-101 blocks serotonin receptors and sigma receptors, over two receptors in the brain that are involved in the regulation of mood, cognition, sleep and anxiety. MIN-117 is meant to block a specific subtype of serotonin receptor called 5-HT1A. MIN-202 is a selective orexin 2 receptor antagonist it is developing in collaboration with Janssen Pharmaceutica NV. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 protein.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: NERV
  • CUSIP:
Key Metrics:
  • Previous Close: $9.40
  • 50 Day Moving Average: $10.84
  • 200 Day Moving Average: $12.30
  • 52-Week Range: $3.45 - $15.84
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.25
  • P/E Growth: 0.00
  • Market Cap: $327.19M
  • Outstanding Shares: 34,807,000
  • Beta: 1.98
Profitability:
  • Return on Equity: -33.78%
  • Return on Assets: -25.83%
Debt:
  • Debt-to-Equity Ratio: 0.04%
  • Current Ratio: 9.18%
  • Quick Ratio: 9.18%
Additional Links:
Companies Related to Minerva Neurosciences:

Analyst Ratings

Consensus Ratings for Minerva Neurosciences (NASDAQ:NERV) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $17.00 (80.85% upside)

Analysts' Ratings History for Minerva Neurosciences (NASDAQ:NERV)
Show:
DateFirmActionRatingPrice TargetDetails
6/8/2016Jefferies Group LLCReiterated RatingBuy$17.00View Rating Details
5/26/2016JMP SecuritiesBoost Price Target$10.00 -> $17.00View Rating Details
(Data available from 2/22/2015 forward)

Earnings

Earnings History for Minerva Neurosciences (NASDAQ:NERV)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/13/2017        
11/3/2016Q316($0.21)($0.24)ViewListenView Earnings Details
8/4/2016Q116($0.30)($0.18)ViewListenView Earnings Details
5/3/2016Q1($0.33)($0.29)ViewListenView Earnings Details
3/14/2016Q4($0.31)($0.34)ViewListenView Earnings Details
11/5/2015Q315($0.36)($0.24)ViewListenView Earnings Details
8/5/2015Q215($0.41)($0.27)ViewN/AView Earnings Details
3/26/2015Q414($0.46)($0.40)ViewN/AView Earnings Details
11/10/2014($2.30)($1.53)ViewN/AView Earnings Details
8/7/2014Q2($0.38)($2.55)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Minerva Neurosciences (NASDAQ:NERV)
Current Year EPS Consensus Estimate: $-0.96 EPS
Next Year EPS Consensus Estimate: $-1.14 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.20)($0.20)($0.20)
Q3 20161($0.23)($0.23)($0.23)
Q4 20161($0.23)($0.23)($0.23)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Minerva Neurosciences (NASDAQ:NERV)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Minerva Neurosciences (NASDAQ:NERV)
Insider Ownership Percentage: 28.10%
Institutional Ownership Percentage: 69.81%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/6/2017Geoff RaceCFOSell21,450$11.02$236,379.00View SEC Filing  
2/6/2017Remy LuthringerCEOSell34,281$11.02$377,776.62View SEC Filing  
1/11/2017Joseph H ReillyCOOSell1,600$12.03$19,248.00View SEC Filing  
1/4/2017Mark S LevineSVPSell17,500$12.00$210,000.00View SEC Filing  
12/27/2016Frederick W AhlholmSVPSell17,000$12.51$212,670.00View SEC Filing  
8/10/2016Venture Associates L Index IIIMajor ShareholderSell1,000,000$10.00$10,000,000.00View SEC Filing  
6/21/2016David KupferDirectorBuy55,635$10.84$603,083.40View SEC Filing  
3/17/2016David KupferDirectorBuy181,488$5.51$999,998.88View SEC Filing  
3/18/2015Care Capital Iii LlcMajor ShareholderSell1,206,700$5.75$6,938,525.00View SEC Filing  
3/18/2015Rubertis Francesco DeDirectorBuy202,634$4.81$974,669.54View SEC Filing  
3/13/2015& Johnson JohnsonMajor ShareholderBuy607,903$4.81$2,924,013.43View SEC Filing  
1/26/2015Care Capital Iii LlcMajor ShareholderSell482,112$5.11$2,463,592.32View SEC Filing  
1/8/2015Care Capital Iii LlcMajor ShareholderSell531,808$7.38$3,924,743.04View SEC Filing  
7/7/2014Care Capital Iii LlcMajor ShareholderBuy737,500$6.00$4,425,000.00View SEC Filing  
7/7/2014Michele OllierDirectorBuy1,620,833$6.00$9,724,998.00View SEC Filing  
7/1/2014Coelho Rogerio VivaldiCEOBuy41,667$6.00$250,002.00View SEC Filing  
7/1/2014Frederick W AhlholmCAOBuy10,000$6.00$60,000.00View SEC Filing  
7/1/2014Geoff RaceCFOBuy33,333$6.00$199,998.00View SEC Filing  
7/1/2014Heek G Jan VanDirectorBuy3,333$6.00$19,998.00View SEC Filing  
7/1/2014Joseph H ReillyInsiderBuy8,333$6.00$49,998.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Minerva Neurosciences (NASDAQ:NERV)
DateHeadline
News IconStock Check: Reviewing the Numbers for Minerva Neurosciences Inc (NERV) - Davidson Register (NASDAQ:NERV)
davidsonregister.com - February 21 at 6:07 PM
finance.yahoo.com logoMinerva Neurosciences to Host R&D Day Focused on Unmet Needs and Emerging Treatment Strategies in Schizophrenia (NASDAQ:NERV)
finance.yahoo.com - February 21 at 6:07 PM
News IconEquity in Focus: Minerva Neurosciences, Inc. (NASDAQ:NERV) - BVN (NASDAQ:NERV)
bvnewsjournal.com - February 18 at 6:45 AM
finance.yahoo.com logoXO1 Founding Management Team Re-Unite to Launch SuperX and Announce $11m Series A Funding With Medicxi and Johnson & Johnson Innovation-JJDC (NASDAQ:NERV)
finance.yahoo.com - February 9 at 5:45 AM
News IconTrading Watch: FCF and Piotroski Score Check for Minerva Neurosciences, Inc. (NASDAQ:NERV) - The Tribune (NASDAQ:NERV)
lakecitytribune.com - February 1 at 7:52 PM
News IconStock Watch: Focusing in on Minerva Neurosciences, Inc. (NASDAQ:NERV) - The Tribune (NASDAQ:NERV)
lakecitytribune.com - January 30 at 7:27 PM
News IconUpdate on Valuation Formula's For Minerva Neurosciences, Inc. (NASDAQ:NERV) - The Tribune (NASDAQ:NERV)
lakecitytribune.com - January 24 at 12:06 AM
zacks.com logoMinerva Presents Additional Data from Schizophrenia Drug (NASDAQ:NERV)
www.zacks.com - January 23 at 9:54 AM
News IconAmplified Volatility Spotted in Shares of Minerva Neurosciences, Inc. (NASDAQ:NERV) - Wall Street Beacon (NASDAQ:NERV)
wsbeacon.com - January 20 at 7:34 PM
investornewswire.com logoMinerva Neurosciences, Inc (NASDAQ:NERV) Records An Impact ... - Investor Newswire (NASDAQ:NERV)
www.investornewswire.com - January 16 at 6:47 AM
News IconStock Getting Tripped Up In Session: Minerva Neurosciences, Inc. (NASDAQ:NERV) - Wall Street Beacon (NASDAQ:NERV)
wsbeacon.com - January 12 at 5:24 AM
marketexclusive.com logoInsider Trading Activity Minerva Neurosciences, Inc (NASDAQ:NERV) – SVP Sold 17500 shares of Stock - Market Exclusive (NASDAQ:NERV)
marketexclusive.com - January 8 at 6:31 PM
marketexclusive.com logoMinerva Neurosciences, Inc. (NASDAQ:NERV) Files An 8-K Other Events - Market Exclusive (NASDAQ:NERV)
marketexclusive.com - January 8 at 6:31 PM
biz.yahoo.com logoMINERVA NEUROSCIENCES, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:NERV)
biz.yahoo.com - January 6 at 7:29 PM
investornewswire.com logoSentiments And Ratings Alert: Minerva Neurosciences, Inc (NASDAQ:NERV) - Investor Newswire (NASDAQ:NERV)
www.investornewswire.com - December 31 at 11:35 PM
marketexclusive.com logoInsider Trading Activity Minerva Neurosciences Inc. (NASDAQ:NERV) – SVP Sold 17000 shares of Stock - Market Exclusive (NASDAQ:NERV)
marketexclusive.com - December 31 at 11:35 PM
marketexclusive.com logoInsider Trading Activity Minerva Neurosciences Inc. (NASDAQ:NERV) – SVP Sold 17,000 shares of Stock (NASDAQ:NERV)
marketexclusive.com - December 30 at 7:40 AM
investornewswire.com logoMinerva Neurosciences, Inc (NASDAQ:NERV) Strong Sell Recommendations At 0 - Investor Newswire (NASDAQ:NERV)
www.investornewswire.com - December 22 at 6:30 AM
globenewswire.com logoMinerva Neurosciences Names Michael Davidson, M.D. as Chief Medical Officer - GlobeNewswire (press release) (NASDAQ:NERV)
globenewswire.com - December 22 at 6:30 AM
us.rd.yahoo.com logo8:39 am Minerva Neurosciences appoints Michael Davidson, M.D., as chief medical officer effective December 19, 2016 (NASDAQ:NERV)
us.rd.yahoo.com - December 20 at 12:44 PM
publicnow.com logoMinerva Neurosciences Names Michael Davidson, M.D. as Chief Medical Officer (NASDAQ:NERV)
www.publicnow.com - December 20 at 12:44 PM
investornewswire.com logoMinerva Neurosciences, Inc (NASDAQ:NERV) Records An Impact Score Of 0 - Investor Newswire (NASDAQ:NERV)
www.investornewswire.com - December 17 at 12:33 AM
News IconInvestor Review: Focusing in on Shares of Minerva Neurosciences Inc. (NERV) - StockTalk Daily (NASDAQ:NERV)
stocktalkdaily.com - December 17 at 12:33 AM
biz.yahoo.com logoMINERVA NEUROSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E (NASDAQ:NERV)
biz.yahoo.com - December 16 at 7:31 PM
investornewswire.com logoStrong Sell Recommendations Of Minerva Neurosciences, Inc (NASDAQ:NERV) At 0 - Investor Newswire (NASDAQ:NERV)
www.investornewswire.com - December 16 at 12:43 AM
marketexclusive.com logoMinerva Neurosciences, Inc. (NASDAQ:NERV) Files An 8-K Regulation FD Disclosure - Market Exclusive (NASDAQ:NERV)
marketexclusive.com - December 6 at 9:46 AM
biz.yahoo.com logoMINERVA NEUROSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:NERV)
biz.yahoo.com - December 6 at 9:46 AM
News IconAutoinjectors Market: Global Market Analysis, Market Outlook and Strategies to 2022 (NASDAQ:NERV)
reports.pr-inside.com - December 5 at 10:06 AM
marketexclusive.com logoMinerva Neurosciences, Inc. (NASDAQ:NERV) Files An 8-K Regulation FD Disclosure (NASDAQ:NERV)
marketexclusive.com - December 5 at 10:06 AM
finance.yahoo.com logoMinerva Neurosciences’ Clinical Data Featured at The American College of Neuropsychopharmacology Annual Meeting (NASDAQ:NERV)
finance.yahoo.com - December 5 at 10:06 AM
finance.yahoo.com logo8:01 am Minerva Neurosciences will present data at the ACNP on December 4-8 (NASDAQ:NERV)
finance.yahoo.com - December 5 at 10:06 AM
finance.yahoo.com logoMinerva Neurosciences' Clinical Data Featured at The American College of Neuropsychopharmacology Annual Meeting (NASDAQ:NERV)
finance.yahoo.com - December 5 at 10:06 AM
News IconKeeping an Eye on Shares of Minerva Neurosciences, Inc. (NASDAQ:NERV) - The Business Journal (NASDAQ:NERV)
belmontbusinessjournal.com - December 3 at 6:00 PM
News IconFCF Score Check on Shares of Minerva Neurosciences, Inc. (NASDAQ:NERV) - Marion Business Daily (NASDAQ:NERV)
marionbusinessdaily.com - December 2 at 6:27 PM
News IconInvestor Monitor: Narrowing in on Minerva Neurosciences, Inc. (NASDAQ:NERV) - The Business Journal (NASDAQ:NERV)
belmontbusinessjournal.com - November 30 at 11:57 PM
investornewswire.com logoBuy Calls Of Minerva Neurosciences, Inc (NASDAQ:NERV) At 0 - Investor Newswire (NASDAQ:NERV)
www.investornewswire.com - November 30 at 6:56 PM
capitalcube.com logoMinerva Neurosciences, Inc. :NERV-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016 (NASDAQ:NERV)
www.capitalcube.com - November 29 at 2:35 PM
News IconValue Focus: Following the Numbers for Minerva Neurosciences, Inc. (NASDAQ:NERV) - The Business Journal (NASDAQ:NERV)
belmontbusinessjournal.com - November 25 at 11:39 AM
finance.yahoo.com logoEdited Transcript of NERV earnings conference call or presentation 3-Nov-16 12:30pm GMT (NASDAQ:NERV)
finance.yahoo.com - November 22 at 6:33 PM
investornewswire.com logoCan Shares Of Minerva Neurosciences, Inc (NASDAQ:NERV) Smash $17? - Investor Newswire (NASDAQ:NERV)
www.investornewswire.com - November 17 at 10:14 AM
News IconIndicators in Focus on Minerva Neurosciences, Inc. (NASDAQ:NERV) - The Business Journal (NASDAQ:NERV)
belmontbusinessjournal.com - November 17 at 10:14 AM
News IconInvestor Notebook: Focusing in on Shares of Minerva Neurosciences Inc. (NERV) - StockTalk Daily (NASDAQ:NERV)
stocktalkdaily.com - November 14 at 6:41 PM
News IconMinerva Neurosciences to Present at Jefferies 2016 London Healthcare Conference on November 17 2016 - EconoTimes (NASDAQ:NERV)
www.econotimes.com - November 11 at 8:59 AM
News IconMinerva Neurosciences to Present at Jefferies 2016 London [..] (NASDAQ:NERV)
www.pr-inside.com - November 10 at 6:09 PM
nasdaq.com logoMinerva Neurosciences to Present at Jefferies 2016 London Healthcare (NASDAQ:NERV)
www.nasdaq.com - November 10 at 6:09 PM
investornewswire.com logoCan Shares Of Minerva Neurosciences, Inc (NASDAQ:NERV) Get To $17? - Investor Newswire (NASDAQ:NERV)
www.investornewswire.com - November 10 at 9:26 AM
News IconMinerva Neurosciences to Present at Jefferies 2016 London Healthcare Conference on November 17, 2016 - P&T Community (NASDAQ:NERV)
www.ptcommunity.com - November 10 at 9:26 AM
finance.yahoo.com logoMinerva Neurosciences to Present at Jefferies 2016 London Healthcare Conference on November 17, 2016 (NASDAQ:NERV)
finance.yahoo.com - November 10 at 9:26 AM
finance.yahoo.com logoMINERVA NEUROSCIENCES, INC. Financials (NASDAQ:NERV)
finance.yahoo.com - November 9 at 6:18 PM
News IconShares Knocked Down Over Past Month: Minerva Neurosciences, Inc. (NASDAQ:NERV) - CSZ News (NASDAQ:NERV)
cincysportszone.com - November 5 at 6:22 PM

Social

What is Minerva Neurosciences' stock symbol?

Minerva Neurosciences trades on the NASDAQ under the ticker symbol "NERV."

Where is Minerva Neurosciences' stock going? Where will Minerva Neurosciences' stock price be in 2017?

2 analysts have issued 12 month price targets for Minerva Neurosciences' shares. Their predictions range from $17.00 to $17.00. On average, they expect Minerva Neurosciences' share price to reach $17.00 in the next twelve months.

When will Minerva Neurosciences announce their earnings?

Minerva Neurosciences is scheduled to release their next quarterly earnings announcement on Monday, March, 13th 2017.

Who owns Minerva Neurosciences stock?

Minerva Neurosciences' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Federated Investors Inc. PA (18.27%), FMR LLC (14.31%), Highland Capital Management LP (3.28%), Franklin Resources Inc. (2.39%), Perceptive Advisors LLC (2.33%) and Orbimed Advisors LLC (1.60%). Company insiders that own Minerva Neurosciences stock include & Johnson Johnson, Care Capital Iii Llc, David Kupfer, Frederick W Ahlholm, Geoff Race, Joseph H Reilly, Mark S Levine, Remy Luthringer, Rubertis Francesco De and Venture Associates L Index III.

Who sold Minerva Neurosciences stock? Who is selling Minerva Neurosciences stock?

Minerva Neurosciences' stock was sold by a variety of institutional investors in the last quarter, including Highland Capital Management LP, Renaissance Technologies LLC, J. Goldman & Co LP and Franklin Resources Inc.. Company insiders that have sold Minerva Neurosciences stock in the last year include Frederick W Ahlholm, Geoff Race, Joseph H Reilly, Mark S Levine, Remy Luthringer and Venture Associates L Index III.

Who bought Minerva Neurosciences stock? Who is buying Minerva Neurosciences stock?

Minerva Neurosciences' stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Russell Investments Group Ltd., State Street Corp, Oxford Asset Management, Marshall Wace LLP and AQR Capital Management LLC. Company insiders that have bought Minerva Neurosciences stock in the last two years include & Johnson Johnson, David Kupfer and Rubertis Francesco De.

How do I buy Minerva Neurosciences stock?

Shares of Minerva Neurosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Minerva Neurosciences stock cost?

One share of Minerva Neurosciences stock can currently be purchased for approximately $9.40.

Minerva Neurosciences (NASDAQ:NERV) Chart for Wednesday, February, 22, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Minerva Neurosciences (NASDAQ:NERV)

Earnings History Chart

Earnings by Quarter for Minerva Neurosciences (NASDAQ:NERV)

Dividend History Chart

Dividend Payments by Quarter for Minerva Neurosciences (NASDAQ:NERV)

Last Updated on 2/22/2017 by MarketBeat.com Staff